期刊文献+

肝癌复发转移的临床与实验研究进展与展望 被引量:6

Clinical and Experimental Studies on Recurrence and Metastasis of Hepatocellular Carcinoma-Progress and Prospect
全文增补中
导出
摘要 90年代以来肝癌已成为我国第二位癌症杀手,为此肝癌的防治至关重要。至今,外科仍然是肝癌获得根治的最好疗法,但复发和转移是进一步改善预后的障碍。近年复发和转移的研究已成为包括肝癌在内所有实体瘤的研究热点。本文复习相关文献,并重点叙述我所的有关工作。临床方面,对亚临床期复发的再切除是进一步提高疗效的有效途径,但复发的预防则困难得多,化疗/免疫/栓塞治疗可能有助。实验研究方面,已建成裸鼠人肝癌高转移模型,研究了与侵袭性相关的分子水平变化(如c─erb—B2、p16、p21、p53、mdm2、VEGF、TGFa、EGF受体、MMP—2、ICAM—1等与侵袭性呈正相关,而nm23—H1、TIMP—2、整合素a5、Kai—1等则与侵袭性呈负相关),并探索了使用反义H─ras、抗HBx/抗CD3的双功能抗体、TNF与TK基因的基因治疗、BB94(基质金属蛋白酶抑制剂)、TNP—470(抗血管生成)等的干预治疗。预期生物治疗、基于分子生物学发现所设计的新疗法、综合干预等可能重要,而针对肿瘤血管的探索对肝癌可能有特殊意义。 Hepatocellular carcinoma(HCC) has become the second cancer killer in China since 1990s, preventionand treatment of HCC are therefore urgently needed. In clinical aspect, surgery remains the best for a curativeoutcome of HCC, unfortunately, recurrence and metastasis are ma jor obstacles for further improve prognosis.Recently, studies on recurrence and metastasis have become attractive fields in all of the solid tumors, includingHCC. This paper has briefly reviewed the related literatures, with special reference to works done in author'sinstitution. In clinical aspect, re-resection has been proved to prolong survival further in patients with subclinical recurrence, however, prevention of recurrence is difficult, postoperative chemo/immuno/embolization mighthelp. In Experimental aspect, a highly metastatic human HCC model in nude mice has been established, invasiveness related molecular events (c - erb - B2, p16, p21, p53 , mdm2, VEGF ) TGFa, EGF receptor , MMP -2, ICAM - 1 were positively related, and nm23 - H1, TIMP -- 2, Integrin a5, Kai - 1 were negativelyrelated) have been studied, and intervention using antisense H --ras, antiHBx/antiCD3 bispecific antibody,gene therapies with TNF and TK genes, BB94 (matrix metalloproteinase inhibitor), TNP - 470 (anti-angio-genic), etc. have also been tried. It is expected that biotherapy, novel approach based on molecular findings,multidisciplinary interventions might be important, and anti-angiogenic approach will of particular implicationfor HCC.
作者 汤钊猷
出处 《世界科技研究与发展》 CSCD 1997年第2期30-34,共5页 World Sci-Tech R&D
关键词 原发性肝癌 实验研究 癌细胞转移 基因治疗 疾病复发 临床研究 Hepatocellular carcinoma primary lice cancer recurrence metastasis clinical experimental
  • 相关文献

参考文献10

  • 1黎乐群,梁水庭,巫山,林进令.小肝癌切除术后复发的监测及复发病灶再治疗的价值[J].实用肿瘤杂志,1994,9(1):28-29. 被引量:9
  • 2Zhao-You Tang M.D.,Ye-Qin Yu M.D.,Xin-Da Zhou M.D.,Zeng-Chen MA M.D.,Ji-Zheu Lu M.D.,Zhi-Ying Lin M.D.,Kang-Da Liu M.D.,Sheng-Long Ye M.D.,Bing-Hui Yang M.D.,Hong-Wei Wang M.D.,Hui-Chuan Sun M.D.. Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma: Evaluation with analysis of 72 patients[J] 1995,World Journal of Surgery(6):784~789
  • 3Zhao-You Tang M.D.,Ye-Qin Yu M.D.,Xin-Da Zhou M.D.,Zeng-Chen Ma M.D.,Bing-Hui Yang M.D.,Zhi-Ying Lin M.D.,Ji-Zhen Lu M.D.,Kang-Da Liu M.D.,Zeng Fan M.D.,Zhao-Chong Zeng M.D.. Treatment of unresectable primary liver cancer: With reference to cytoreduction and sequential resection[J] 1995,World Journal of Surgery(1):47~52
  • 4Shigeki Arii,Junji Tanaka,Kenichi Fujita,Kazunobu Monden,Masayuki Imamura. A retrospective study of the preventive effect of transarterial chemotherapy for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy[J] 1994,Journal of Hepato - Biliary - Pancreatic Surgery(3):263~266
  • 5Xin-Da Zhou,Zhao-You Tang,Ye-Qin Yu,Bing-Hui Yang,Ji-Zhen Lu,Zhi-Ying Lin,Zeng-Chen Ma,Bo-Heng Zhang. Recurrence after resection ofα-fetoprotein-positive hepatocellular carcinoma[J] 1994,Journal of Cancer Research and Clinical Oncology(6):369~373
  • 6Edward C. S. Lai,John Wong. Analysis of factors affecting long-term survival of patients with hepatocellular carcinoma following hepatectomy[J] 1994,Journal of Hepato - Biliary - Pancreatic Surgery(2):113~117
  • 7Chai Xiyun,Chen Huili,Zhou Xiaomei,Qian Lianfang,Chen Sihong,Jiang Huiqiu,Gu Jianren. Expression of oncogenes during induced differentiation of human hepatocarcinoma cell line[J] 1994,Chinese Journal of Cancer Research(1):3~8
  • 8Tang Zhaoyou,Yu Yeqin,Zhou Xinda,Ma Zengchen,Liu Kangda,Lu Jizhen,Lin Zhiying,Zeng Zhaochong,Fan Zhen,Yang Binghui,Xie Hong. The role of targeting therapy in cytoreduction and sequential resection of unresectable hepatocellular carcinoma[J] 1994,Chinese Journal of Cancer Research(1):24~30
  • 9Zhang Boheng,Zhou Zinda,Yu Yeqin,Tang Zhaoyou. Risk factors for recurrence in patients with hepato-cellular carcinoma after radical resection[J] 1994,Chinese Journal of Cancer Research(1):58~62
  • 10Lu Jizhen,Li Bingxin,Liu Kangda,Yu Yeqin,Tang Zhaoyou. Alternating chemotherapy and fractionated radiotherapy as a modality for the treatment of primary liver cancer[J] 1994,Chinese Journal of Cancer Research(1):69~73

共引文献8

同被引文献30

  • 1金若敏,陈长勋,沈艳,王文群,郑志仁,刘涤,胡之璧.黄芪毛状根与黄芪药理作用的比较研究[J].上海中医药大学上海市中医药研究院学报,1996,10(2):98-101. 被引量:3
  • 2周伟平,吴孟超,陈汉,姚小平,钱光相,杨甲梅,屠振兴,崔贞福.肝癌切除加免疫化疗对术后复发的影响[J].中华外科杂志,1995,33(1):35-37. 被引量:32
  • 3陈鸿瑾,刘桂东,王昆,沈幼贞.黄芪对大鼠肾缺血再灌流时过氧化脂质含量的影响[J].徐州医学院学报,1989,9(3):186-186. 被引量:10
  • 4陈长勋.银杏叶提取物改善小鼠记忆作用的研究[J].中国中药杂志,1991,16(11):681-681.
  • 5许沈华.体外建立人大肠癌细胞株及其应用进展[J].国外医学肿瘤分册,1983,10:217-222.
  • 6王丹.nm23基因是否是转移抑制基因[J].国外医学肿瘤分册,1995,22:52-54.
  • 7陆继珍 刘康达 等.人体肝细胞癌血供的观察[J].肿瘤,1986,6(4):183-184.
  • 8Zacherl J, Scheuba C, Imhof M, et al. Current value of intraoperative sonography during surgery for hepatic neoplasms. World J Surg, 2002, 26:550-554.
  • 9Fan MH, Chang AE. Resection of liver tumors: technical aspects. Surg Oncol, 2002, 10:139-152.
  • 10Makuuchi M, Imamura H, Sugawara Y, et al. Progress in surgical treatment of hepatocellular carcinoma. Oncology, 2002, 62 (Suppl) 1:74-81.

引证文献6

二级引证文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部